Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Acitrate Plus - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Acitrate Plus

Approved

STANDARD

Acitrate Plus

Cooper Pharma Limited🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: a8543b27586a86cb
Company: Cooper Pharma Limited
Type: Standard

Approval Details

Approval Id: a8543b27586a86cb
Drug Approval Philippines Name: Acitrate Plus
Product Name: Acitrate Plus
Registration Number: DRP-14484-04
Brand Name: Acitrate Plus
Generic Name: Potassium citrate
Dosage Form: Extended-Release Tablet
Dosage Strength: 1.620 g (15 mEq)
Manufacturer: Cooper Pharma Limited
Importer: Ambica International Corporation
Distributor: Scriptmed, Inc.
Issuance Date: 25 April 2024
Expiry Date: 12 September 2028
Pharmacologic Category: Antiurolithic
Classification: Prescription Drug (Rx)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

a8543b27586a86cb

Type

Standard

Back to Philippines FDA Approvals